Sensitivity and Prognostic Utility of Serum FLC vs FLC-MS Assessments in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma Treated With Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Blood Cancer J 2024 Mar 18;14(1)50, HV Giles, MT Drayson, B Kishore, C Pawlyn, M Kaiser, G Cook, R de Tute, RG Owen, D Cairns, T Menzies, FE Davies, GJ Morgan, G Pratt, GH JacksonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.